Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDTNASDAQ:CMNDNASDAQ:SRNENASDAQ:TCRT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDTConduit Pharmaceuticals$3.48-15.3%$9.16$3.25▼$4,905.00$39.46M2.39111,327 shs182,359 shsCMNDClearmind Medicine$0.97-3.5%$1.01$0.85▼$2.30$4.12M0.89877,267 shs24,818 shsSRNESorrento Therapeutics$0.00-18.8%$0.00$0.00▼$0.02$717K1.1384,601 shs121,207 shsTCRTAlaunos Therapeutics$2.66+0.8%$2.48$1.31▼$11.70$4.36M-1.08136,315 shs3,912 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDTConduit Pharmaceuticals-15.33%-40.51%-58.31%-79.83%-99.92%CMNDClearmind Medicine-3.50%-2.53%-1.17%-25.19%-16.81%SRNESorrento Therapeutics-18.75%+18.18%+44.44%+116.67%-90.00%TCRTAlaunos Therapeutics+0.76%-6.34%+8.13%+58.33%-74.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDTConduit Pharmaceuticals0.6899 of 5 stars0.04.00.00.01.91.70.0CMNDClearmind Medicine0.1304 of 5 stars0.02.00.00.00.61.70.0SRNESorrento TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATCRTAlaunos Therapeutics0.4167 of 5 stars0.05.00.00.00.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDTConduit Pharmaceuticals 4.00Strong BuyN/AN/ACMNDClearmind Medicine 0.00N/AN/AN/ASRNESorrento Therapeutics 0.00N/AN/AN/ATCRTAlaunos Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDTConduit PharmaceuticalsN/AN/AN/AN/A($0.62) per shareN/ACMNDClearmind MedicineN/AN/AN/AN/A$0.73 per shareN/ASRNESorrento Therapeutics$60.32M0.01N/AN/AN/A∞TCRTAlaunos Therapeutics$10K436.24N/AN/A$3.93 per share0.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDTConduit Pharmaceuticals-$540K-$35.65N/A∞N/AN/AN/A-328.67%N/ACMNDClearmind Medicine-$5.26M-$1.22N/A∞N/AN/A-129.21%-61.15%6/12/2025 (Estimated)SRNESorrento Therapeutics-$572.84MN/A0.00∞N/AN/AN/AN/AN/ATCRTAlaunos Therapeutics-$35.14MN/A0.00∞N/AN/A-267.77%-209.18%8/12/2025 (Estimated)Latest SRNE, CMND, TCRT, and CDT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CDTConduit PharmaceuticalsN/A-$19.80N/A-$1.32N/AN/A5/15/2025Q1 2025TCRTAlaunos Therapeutics-$4.50-$0.67+$3.83-$0.67N/A$0.00 million3/28/2025Q4 2024CDTConduit PharmaceuticalsN/A-$304.95N/A-$20.33N/AN/A3/13/2025Q1 2025CMNDClearmind MedicineN/A-$0.24N/A-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDTConduit PharmaceuticalsN/AN/AN/AN/AN/ACMNDClearmind MedicineN/AN/AN/AN/AN/ASRNESorrento TherapeuticsN/AN/AN/AN/AN/ATCRTAlaunos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDTConduit PharmaceuticalsN/A0.120.12CMNDClearmind Medicine0.011.721.72SRNESorrento TherapeuticsN/AN/AN/ATCRTAlaunos TherapeuticsN/A4.304.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDTConduit Pharmaceuticals3.29%CMNDClearmind Medicine96.05%SRNESorrento Therapeutics0.02%TCRTAlaunos Therapeutics27.72%Insider OwnershipCompanyInsider OwnershipCDTConduit Pharmaceuticals30.93%CMNDClearmind MedicineN/ASRNESorrento Therapeutics2.60%TCRTAlaunos Therapeutics5.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDTConduit Pharmaceuticals311.34 million710,000Not OptionableCMNDClearmind MedicineN/A4.27 millionN/ANot OptionableSRNESorrento Therapeutics800551.28 million536.95 millionNo DataTCRTAlaunos Therapeutics401.64 million1.52 millionNo DataSRNE, CMND, TCRT, and CDT HeadlinesRecent News About These CompaniesPMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)May 14, 2025 | globenewswire.comAlaunos Therapeutics announces board member resignationApril 20, 2025 | investing.comThese 3 Healthcare Stocks Show Serious Muscle Amid Trump Tariff Turmoil: Are Retail Traders Feeling Bullish?April 7, 2025 | msn.comPrecigen Terminates License Agreement With Alaunos TherapeuticsOctober 11, 2024 | marketwatch.comAfter axing its sole clinical prospect last year, Alaunos cuts ties with PrecigenOctober 11, 2024 | fiercebiotech.comAlaunos Therapeutics Ends Licensing Deal, Reassesses StrategyOctober 11, 2024 | finance.yahoo.comAlaunos Therapeutics (NASDAQ:TCRT) Stock, Short Interest ReportSeptember 26, 2024 | benzinga.comAlaunos Therapeutics (NASDAQ:TCRT) Stock Quotes, Forecast and News SummarySeptember 26, 2024 | benzinga.comStella Pharma Corporation (4888.T) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comTCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024May 16, 2024 | investorplace.comRevolution Medicines: An Expensive Shot At A Massive Market OpportunityApril 12, 2024 | seekingalpha.comTCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023April 8, 2024 | investorplace.comBiora Therapeutics announces $6M registered direct offering and concurrent private placementApril 1, 2024 | msn.comSharp increase in TCRT’s short interest leads to surge in days-to-cover ratioFebruary 1, 2024 | knoxdaily.comAlaunos Therapeutics Announces 1-for-15 Reverse Stock SplitJanuary 31, 2024 | msn.comWerewolf Therapeutics Inc (HOWL)January 31, 2024 | investing.comAlaunos Therapeutics Inc [TCRT] Insider Boyle Kevin S. Sr. sells 68,014 Shares – Latest Insider ActivityJanuary 3, 2024 | knoxdaily.comAlaunos Therapeutics Stock (NASDAQ:TCRT) Dividends: History, Yield and DatesDecember 28, 2023 | benzinga.comTCRT Shares Experience Decline in ValueNovember 17, 2023 | knoxdaily.comRecap: Alaunos Therapeutics Q3 EarningsNovember 14, 2023 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSRNE, CMND, TCRT, and CDT Company DescriptionsConduit Pharmaceuticals NASDAQ:CDT$3.48 -0.63 (-15.33%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.57 +0.09 (+2.61%) As of 05/23/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.Clearmind Medicine NASDAQ:CMND$0.96 -0.04 (-3.50%) Closing price 05/23/2025 03:52 PM EasternExtended Trading$0.96 -0.01 (-0.83%) As of 05/23/2025 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.Sorrento Therapeutics NASDAQ:SRNE$0.0013 0.00 (-18.75%) As of 05/23/2025 03:32 PM EasternSorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.Alaunos Therapeutics NASDAQ:TCRT$2.66 +0.02 (+0.76%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$2.54 -0.12 (-4.47%) As of 05/23/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
